|
1
|
Segovia MC, Chacra W and Gordon SC:
Adefovir dipivoxil in chronic hepatitis B: history and current
uses. Expert Opin Pharmacother. 13:245–254. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Shepherd J, Jones J, Takeda A, Davidson P
and Price A: Adefovir dipivoxil and pegylated interferon alfa-2a
for the treatment of chronic hepatitis B: A systematic review and
economic evaluation. Health Technol Assess. 10(iii-iv): xi–xiv,
1–183. 2006.
|
|
3
|
Stein LL and Loomba R: Drug targets in
hepatitis B virus infection. Infect Disord Drug Targets. 9:105–116.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Chen Y and Ju T: Comparative meta-analysis
of adefovir dipivoxil monotherapy and combination therapy of
adefovir dipivoxil and lamivudine for lamivudine-resistant chronic
hepatitis B. Int J Infect Dis. 16:e152–158. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Han SH: Natural course, therapeutic
options and economic evaluation of therapies for chronic hepatitis
B. Drugs. 66:1831–1851. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Girgis CM, Wong T, Ngu MC, Emmett L,
Archer KA, Chen RC and Seibel MJ: Hypophosphataemic osteomalacia in
patients on adefovir dipivoxil. J Clin Gastroenterol. 45:468–473.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Law ST, Li KK and Ho YY: Nephrotoxicity,
including acquired Fanconi's syndrome, caused by adefovir
dipivoxil-is there a safe dose? J Clin Pharm Ther. 37:128–131.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Li L, Dong GF, Zhang X and Xie YS:
Adefovir dipivoxil-induced Fanconi syndrome and hypophosphatemic
osteomalacia associated with muscular weakness in a patient with
chronic hepatitis B. Nan Fang Yi Ke Da Xue Xue Bao. 31:19562011.(In
Chinese). PubMed/NCBI
|
|
9
|
Li X, Shen M, Sun WJ, Huang ZX, An N and
Zhang JJ: Misdiagnosis of Bone Metastasis Cancer After Using
Adefovir Dipivoxi in a Hepatitis B Patient with Fanconi Syndrome.
Indian J Hematol Blood Transfus. 32:329–331. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Lee YS, Kim BK, Lee HJ and Dan J:
Pathologic Femoral Neck Fracture Due to Fanconi Syndrome Induced by
Adefovir Dipivoxil Therapy for Hepatitis B. Clin Orthop Surg.
8:232–236. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Stevens LA, Schmid CH, Greene T, Zhang YL,
Beck GJ, Froissart M, Hamm LL, Lewis JB, Mauer M, Navis GJ, et al:
Comparative performance of the CKD epidemiology collaboration
(CKD-EPI) and the modification of diet in renal disease (MDRD)
study equations for estimating GFR levels above 60 ml/min/1.73 m2.
Am J Kidney Dis. 56:486–495. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Levey AS, Stevens LA, Schmid CH, Zhang YL,
Castro AF III, Feldman HI, Kusek JW, Eggers P, Van Lente F, Greene
T, et al: A new equation to estimate glomerular filtration rate.
Ann Intern Med. 150:604–612. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Zeng AZ, Lu P, Deng H, Cai SF, Yang C, Xin
XJ, Guo JJ, Li QL, Deng XH and Huang AL: Dissection of mechanism
for the adefovir dipivoxil resistance in chronic hepatitis B
patients. Zhonghua ganzangbing zazhi. 17:730–734. 2009.PubMed/NCBI
|
|
14
|
Kahn J, Lagakos S, Wulfsohn M, Cherng D,
Miller M, Cherrington J, Hardy D, Beall G, Cooper R, Murphy R, et
al: Efficacy and safety of adefovir dipivoxil with antiretroviral
therapy: A randomized controlled trial. JAMA. 282:2305–2312. 1999.
View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Brinkman K, ter Hofstede HJ, Burger DM,
Smeitink JA and Koopmans PP: Adverse effects of reverse
transcriptase inhibitors: Mitochondrial toxicity as common pathway.
AIDS. 12:1735–1744. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Fontana RJ: Side effects of long-term oral
antiviral therapy for hepatitis B. Hepatology. 49:(Suppl 5).
S185–S195. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Tsilchorozidou T and Yovos JG:
Hypophosphataemic osteomalacia due to de Toni-Debre-Fanconi
syndrome in a 19-year old girl. Hormones. 4:171–176. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Shaikh A, Wiisanen ME, Gunderson HD and
Leung N: Acquired Fanconi syndrome after treatment with
capecitabine, irinotecan, and bevacizumab. Ann Pharmacother.
43:1370–1373. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Lemire J and Kaplan BS: The various renal
manifestations of the nephropathic form of cystinosis. Am J
Nephrol. 4:81–85. 1984. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Cleveland WW, Adams WC, Mann JB and Nyhan
WL: Acquired Fanconi Syndrome Following Degraded Tetracycline. J
Pediatr. 66:333–342. 1965. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Schwartz JH and Schein P: Fanconi syndrome
associated with cephalothin and gentamicin therapy. Cancer.
41:769–772. 1978. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Rossi R, Rath B, Ullrich K and Ehrich JH:
Ifosfamide-induced nephrotoxicity. Monatsschr Kinderheilkd.
141:594–601. 1993.(In German). PubMed/NCBI
|
|
23
|
Knorr M, Schaper J, Harjes M, Mayatepek E
and Rosenbaum T: Fanconi syndrome caused by antiepileptic therapy
with valproic Acid. Epilepsia. 45:868–871. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Venkatesan EP, Pranesh MB, Gnanashanmugam
G and Balasubramaniam J: Tenofovir induced Fanconi syndrome: A rare
cause of hypokalemic paralysis. Indian J Nephrol. 24:108–109. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Zhu LN, Mou LJ, Hu Y and Chen JX: Fanconi
syndrome caused by low-dose adefovir dipivoxil. Saudi Med J.
35:309–313. 2014.PubMed/NCBI
|
|
26
|
Yoshinami T, Yagi T, Sakai D, Sugimoto N
and Imamura F: A case of acquired Fanconi syndrome induced by
zoledronic acid. Intern Med. 50:1075–1079. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Zheng F, Zhao S and Li X: The clinical and
biochemical manifestations of Fanconi syndrome: A report of 42
cases. Zhonghua Nei Ke Za Zhi. 39:735–738. 2000.(In Chinese).
PubMed/NCBI
|
|
28
|
Belmouaz S, Sechet A, Fernandez B, Ayache
RA, Desport E, Bauwens M, Goujon JM, Gombert JM, Bridoux F and
Touchard G: Tubulo-interstitial nephritis with Fanconi syndrome in
Behcet disease. Nephrol Dial Transplant. 22:2079–2083. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Ghiculescu RA and Kubler PA:
Aminoglycoside-associated Fanconi syndrome. Am J Kidney Dis.
48:e89–e93. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Gupta SK: Tenofovir-associated Fanconi
syndrome: Review of the FDA adverse event reporting system. AIDS
Patient Care STDS. 22:99–103. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Kazory A, Singapuri S, Wadhwa A and Ejaz
AA: Simultaneous development of Fanconi syndrome and acute renal
failure associated with cidofovir. J Antimicrob Chemother.
60:193–194. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Francois H, Coppo P, Hayman JP, Fouqueray
B, Mougenot B and Ronco P: Partial fanconi syndrome induced by
imatinib therapy: A novel cause of urinary phosphate loss. Am J
Kidney Dis. 51:298–301. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Aslam N, Pesacreta M, Bastacky SI, McHale
T, Huston A, Palevsky PM and Weisbord SD: Light chain-associated
Fanconi syndrome with nephrotic-range proteinuria. Am J Kidney Dis.
47(A57): e43–e45. 2006.
|
|
34
|
Koike K, Lida S, Usui M, Matsumoto Y,
Fukami K, Ueda S, Tamaki K, Kato S and Okuda S: Adult-onset acute
tubulointerstitial nephritis and uveitis with Fanconi syndrome.
Case report and review of the literature. Clin Nephrol. 67:255–259.
2007. View
Article : Google Scholar : PubMed/NCBI
|
|
35
|
D'Ythurbide G, Goujard C, Méchaï F, Blanc
A, Charpentier B and Snanoudj R: Fanconi syndrome and nephrogenic
diabetes insipidus associated with didanosine therapy in HIV
infection: A case report and literature review. Nephrol Dial
Transplant. 22:3656–3659. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Izzedine H, Launay-Vacher V and Deray G:
Antiviral drug-induced nephrotoxicity. Am J Kidney Dis. 45:804–817.
2005. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Cihlar T, Lin DC, Pritchard JB, Fuller MD,
Mendel DB and Sweet DH: The antiviral nucleotide analogs cidofovir
and adefovir are novel substrates for human and rat renal organic
anion transporter 1. Mol Pharmacol. 56:570–580. 1999.PubMed/NCBI
|
|
38
|
Ho ES, Lin DC, Mendel DB and Cihlar T:
Cytotoxicity of antiviral nucleotides adefovir and cidofovir is
induced by the expression of human renal organic anion transporter
1. J Am Soc Nephrol. 11:383–393. 2000.PubMed/NCBI
|
|
39
|
Shimizu M, Furusyo N, Ikezaki H, Ogawa E,
Hayashi T, Ihara T, Harada Y, Toyoda K, Murata M and Hayashi J:
Predictors of kidney tubular dysfunction induced by adefovir
treatment for chronic hepatitis B. World J Gastroenterol.
21:2116–2123. 2015.PubMed/NCBI
|
|
40
|
Kearney BP, Ramanathan S, Cheng AK,
Ebrahimi R and Shah J: Systemic and renal pharmacokinetics of
adefovir and tenofovir upon coadministration. J Clin Pharmacol.
45:935–940. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Jung YK, Yeon JE, Choi JH, Kim CH, Jung
ES, Kim JH, Park JJ, Kim JS, Bak YT and Byun KS: Fanconi's syndrome
associated with prolonged adefovir dipivoxil therapy in a hepatitis
B virus patient. Gut Liver. 4:389–393. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Ning H, Li K, Li W, Ding G, Xiao E, Mao Z,
Kang Y and Shang J: Adefovir dipivoxil effects on and related
factors of blood phosphorus metabolism in patients with chronic
hepatitis B. Zhonghua ganzangbing zazhi. 23:590–593.
2015.PubMed/NCBI
|
|
43
|
Ha NB, Ha NB, Garcia RT, Trinh HN, Vu AA,
Nguyen HA, Nguyen KK, Levitt BS and Nguyen MH: Renal dysfunction in
chronic hepatitis B patients treated with adefovir dipivoxil.
Hepatology. 50:727–734. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Krag A, Wiest R, Albillos A and Gluud LL:
The window hypothesis: Haemodynamic and non-haemodynamic effects of
beta-blockers improve survival of patients with cirrhosis during a
window in the disease. Gut. 61:967–969. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
García-Compeán D, González-González JA,
Lavalle-González FJ, González-Moreno EI, Maldonado-Garza HJ and
Villarreal-Pérez JZ: The treatment of diabetes mellitus of patients
with chronic liver disease. Ann Hepatol. 14:780–788. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Ge PS and Runyon BA: Treatment of Patients
with Cirrhosis. N Engl J Med. 375:767–777. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Cundy KC: Clinical pharmacokinetics of the
antiviral nucleotide analogues cidofovir and adefovir. Clin
Pharmacokinet. 36:127–143. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Jafari A, Khalili H and Dashti-Khavidaki
S: Tenofovir-induced nephrotoxicity: Incidence, mechanism, risk
factors, prognosis and proposed agents for prevention. Eur J Clin
Pharmacol. 70:1029–1040. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Vassalotti JA, Centor R, Turner BJ, Greer
RC, Choi M and Sequist TD: National Kidney Foundation Kidney
Disease Outcomes Quality Initiative: Practical Approach to
Detection and Management of Chronic Kidney Disease for the Primary
Care Clinician. Am J Med. 129:153–162.e7. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
50
|
Safaei-Asl A, Enshaei M, Heydarzadeh A and
Maleknejad S: Correlation between cystatin C-based formulas,
Schwartz formula and urinary creatinine clearance for glomerular
filtration rate estimation in children with kidney disease. J Renal
Inj Prev. 5:157–161. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
51
|
Stevens LA, Coresh J, Greene T and Levey
AS: Assessing kidney function-measured and estimated glomerular
filtration rate. N Engl J Med. 354:2473–2483. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
52
|
Zhang L, Zhang P, Wang F, Zuo L, Zhou Y,
Shi Y, Li G, Jiao S, Liu Z, Liang W and Wang H: Prevalence and
factors associated with CKD: A population study from Beijing. Am J
Kidney Dis. 51:373–384. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
53
|
Weiner DE, Tighiouart H, Elsayed EF,
Griffith JL, Salem DN and Levey AS: Uric acid and incident kidney
disease in the community. J Am Soc Nephrol. 19:1204–1211. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
54
|
Zhang L, Wang F, Wang L, Wang W, Liu B,
Liu J, Chen M, He Q, Liao Y, Yu X, et al: Prevalence of chronic
kidney disease in China: A cross-sectional survey. Lancet.
379:815–822. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
55
|
Chen N, Wang W, Huang Y, Shen P, Pei D, Yu
H, Shi H, Zhang Q, Xu J, Lv Y and Fan Q: Community-based study on
CKD subjects and the associated risk factors. Nephrol Dial
Transplant. 24:2117–2123. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
56
|
Deng CL, Song XW, Liang HJ, Feng C, Sheng
YJ and Wang MY: Chronic hepatitis B serum promotes apoptotic damage
in human renal tubular cells. World J Gastroenterol. 12:1752–1756.
2006. View Article : Google Scholar : PubMed/NCBI
|
|
57
|
Jaryal A, Kumar V and Sharma V: Renal
disease in patients infected with hepatitis B virus. Trop
Gastroenterol. 36:220–228. 2015. View
Article : Google Scholar : PubMed/NCBI
|
|
58
|
Amet S, Bronowicki JP, Thabut D, Zoulim F,
Bourliere M, Mathurin P, de Ledinghen V, Benhamou Y, Larrey DG,
Janus N, et al: Prevalence of renal abnormalities in chronic HBV
infection: The HARPE study. Liver Int. 35:148–155. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
59
|
De Silva ST, Perera RP, Niriella MA,
Pathmeswaran A and de Silva HJ: Frequency, pattern and short-term
outcome of chronic renal dysfunction in patients with cirrhosis: A
prospective study using HRS and ADQI-IAC criteria. Eur J
Gastroenterol Hepatol. 26:1296–1299. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
60
|
Lim YS, Larson TS, Benson JT, Kamath PS,
Kremers WK, Therneau TM and Kim WR: Serum sodium, renal function,
and survival of patients with end-stage liver disease. J Hepatol.
52:523–528. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
61
|
Kim SU, Han KH, Nam CM, Park JY, Kim do Y,
Chon CY and Ahn SH: Natural history of hepatitis B virus-related
cirrhotic patients hospitalized to control ascites. J Gastroenterol
Hepatol. 23:1722–1727. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
62
|
Minde Z, Yimin M, Guangbi Y, JinLin H, Hao
W, Hong R, Yuming W, Xiaqiu Z, Daozhen X, Yagang C, et al: Five
years of treatment with adefovir dipivoxil in Chinese patients with
HBeAg-positive chronic hepatitis B. Liver Int. 32:137–146. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
63
|
George N, Basu G, Mohapatra A, Zachariah
U, Abraham P, Korula A, Varughese S, Jacob CK and Tamilarasi V:
Adefovir nephrotoxicity in a renal allograft recipient. Indian J
Nephrol. 25:180–183. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
64
|
Ho ES, Lin DC, Mendel DB and Cihlar T:
Cytotoxicity of antiviral nucleotides adefovir and cidofovir is
induced by the expression of human renal organic anion transporter
1. J Am Soc Nephrol. 11:383–393. 2000.PubMed/NCBI
|
